The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) ...

Approved presentations of SELARSDI are 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection ... concomitant methotrexate use did not appear to influence the ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , and Alvotech today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDItm (ustekinumab-aekn) ...

Methotrexate (MTX), an older oral DMARD ... patients and managed-care groups have a preference for subcutaneous administration (limiting the impact of infusion-based therapies on market share ...